Continuous and flash glucose monitoring in type 2 diabetes awaiting coverage decision in Norway

Norway has a national system for the introduction of new health technologies within the specialist health service (“New Methods” framework) through either a national or hospital-based health technology assessment. This framework is mandatory for all innovations before being funded.

Continuous glucose monitoring (real-time CGM) and flash glucose monitoring (intermittently scanned CGM) in type 2 diabetes have been evaluated within the "New Methods" framework since June 2023.

In January 2026, the Norwegian Medical Products Agency (NOMA) report “Continuous glucose monitoring in type 2 diabetes treated with insulin” was published. NOMA uses the term "continuous glucose monitoring" to refer to both real-time CGM (rtCGM) and intermittently scanned CGM (isCGM, also called flash glucose monitoring). Key conclusions included the following:

• The health economic analysis indicates that CGM may provide additional health benefits compared with self-monitoring of blood glucose (SMBG) for selected insulin-treated individuals with type 2 diabetes, particularly those requiring specialist follow-up.
• In contrast, for the overall population of insulin-treated individuals with type 2 diabetes, no clinically meaningful difference between CGM and SMBG was observed when HbA1c was used as the primary outcome.
• The cost-effectiveness of CGM is therefore highly dependent on long-term user adherence, sustained glycemic benefits, and the time horizon applied in the analysis. When diabetes-related complications are incorporated into the modelling, potential long-term benefits may outweigh costs for patients managed in specialist healthcare settings.
• The possible introduction of CGM for insulin-treated people with type 2 diabetes will increase the need for resources and the demand for healthcare personnel, especially specialist nurses. The budgetary consequences for the regional health authorities will therefore depend on how the follow-up of continuous tissue glucose meters is organized and how many patients use the technology.

As the HTA recommendations are now available, the Decision Forum (composed of four Regional Health Authorities) needs to make a coverage decision on rtCGM and isCGM for type 2 diabetes patients.

See full details in Norwegian here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.